About NovartisNovartis AG is a world leader in pharmaceuticals and consumer health.

About NovartisNovartis AG is a world leader in pharmaceuticals and consumer health. In 2003, the Group posted sales of USD 24.9 billion and net income of USD 5. The Group invested approximately USD 3.8 billion in R & D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 80,000 people and operate in over 140 countries around the world. For further information, please contact.

References1 Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ, on behalf of the TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial , reduction in ulcer complications: a randomized controlled trial. Lancet 2004, 364 :665-674.About the StudyThis phase II, inscribed multicentre, open-label, single-arm study regorafenib 49 previously the untreated patients with metastatic or unresectable, mostly clearly RCC. The American daily three weeks on one / a week free unscheduled administered. The primary outcome was the response rate rate RECIST. The secondary endpoints included safety, progression-free survival the duration of response, duration of stable disease, pharmacokinetics and biomarker data.

Both comments and pings are currently closed.

Comments are closed.

Powered by WordPress | Designed by: redshirtarmy.com | Thanks to redshirtarmy.com